<DOC>
	<DOCNO>NCT00073918</DOCNO>
	<brief_summary>This phase II trial study well give iodine I 131 tositumomab together etoposide cyclophosphamide follow autologous stem cell transplant work treat patient relapsed refractory non-Hodgkin 's lymphoma . Radiolabeled monoclonal antibody , iodine I 131 tositumomab , find cancer cell deliver radioactive cancer-killing substance without harm normal cell . Drugs use chemotherapy , etoposide cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Combining radiolabeled monoclonal antibody combination chemotherapy autologous stem cell transplant may kill cancer cell</brief_summary>
	<brief_title>Iodine I 131 Tositumomab , Etoposide Cyclophosphamide Followed Autologous Stem Cell Transplant Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess progression-free survival patient receive 131 I label tositumomab antibody , etoposide ( VP-16 ) cyclophosphamide ( CY ) follow autologous transplantation . II . To examine potential efficacy 131 I label tositumomab antibody , etoposide ( VP-16 ) cyclophosphamide ( CY ) follow autologous transplantation . SECONDARY OBJECTIVES : I . To assess overall survival patient receive 131 I label tositumomab antibody , etoposide ( VP-16 ) cyclophosphamide ( CY ) follow autologous transplantation . II . To evaluate toxicity tolerability therapy . OUTLINE : RADIOIMMUNOTHERAPY : Patients receive test dose iodine I 131 tositumomab intravenously ( IV ) day -24 determine biodistribution . Patients receive therapeutic iodine I 131 tositumomab IV approximately 40-60 minute day -14 enter radiation isolation day -4 . CHEMOTHERAPY : Patients receive etoposide IV day -4 cyclophosphamide IV day -2 . AUTOLOGOUS STEM CELL TRANSPLANTATION : Patients undergo autologous peripheral blood stem cell transplant day 0 . After completion study treatment , patient follow 1 , 3 , 6 , 12 month annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Patients must histologically confirm diagnosis lymphoma express cluster differentiation ( CD ) 20 antigen generally must fail least one prior standard systemic therapy ; exception mantle cell lymphoma ( MCL ) patient , may enrol first complete remission ( CR ) accordance current transplant standard care patient Note : Patients clinically nontransformed follicular lymphoma require repeat biopsy immunophenotyping since tumor uniformly reactive tositumomab antibody Patients must tumor burden &lt; 500cc compute tomography ( CT ) magnetic resonance ( MRI ) volumetric measurement must splenomegaly time enrollment ; splenomegaly define spleen volume &gt; 2 standard deviation mean spleen volume body weight ratio ( mean = 3.84 cc/kg , SD = 1.53 cc/kg ) ; thus , patient &gt; 6.9cc/kg defined splenomegaly ; patient splenomegaly think due G CSF/GMCSF effect due lymphomatous involvement spleen deem eligible approval investigator Patients must normal renal function ( creatinine [ Cr ] &lt; 2.0 ) Patients must normal hepatic function ( bilirubin &lt; 1.5mg/dL ) , exception patient think Gilbert 's syndrome , may total bilirubin 1.5mg/dL All patient eligible therapeutic study must autologous hematopoietic stem cell ( 2 x 10^6 CD34+ cells/kg ) harvest cryopreserved Patients must expect survival &gt; 60 day must free major infection Circulating antimouse antibody ( HAMA ) Systemic antilymphoma therapy give within 30 day prior anticipate treatment date Inability understand give inform consent Prior radiation &gt; 20 Gy critical normal organ ( e.g. , lung , liver , spinal cord , 25 % red marrow ) Central nervous system lymphoma Other serious medical condition consider represent contraindication autologous stem cell transplant ( ASCT ) ( e.g. , active coronary artery disease , pulmonary dysfunction [ force expiratory volume 1 second ( FEV1 ) &lt; 70 % expect , Vital Capacity &lt; 70 % expect , diffuse capacity lung carbon monoxide ( DLCO ) &lt; 50 % , patient supplemental oxygen ] , AIDS , etc . ) Pregnancy Prior bone marrow stem cell transplant Presence circulate lymphoma cell morphology flow cytometry ( &gt; = 0.1 % ) near time peripheral blood stem cell ( PBSC ) collection unpurged PBSC use Southwest Oncology Group ( SWOG ) performance status &gt; = 2.0 Unable perform selfcare radiation isolation Patients chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma/well differentiate lymphocytic lymphoma ( ineligible tumor express low surface density CD20 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>